FDA Drug Approvals for Cancer in 2015

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Jessica Cheng, MD

Ivonescimab Improves PFS Vs Pembrolizumab in Advanced PD-L1+ NSCLC

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

Caroline Seymour

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

Russ Conroy

Novel TKI Exhibits Durable Responses in HER2-Mutated NSCLC

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Ariana Pelosci

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Related Content

Chris Ryan

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Jessica Cheng, MD

Ivonescimab Improves PFS Vs Pembrolizumab in Advanced PD-L1+ NSCLC

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Caroline Seymour

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Russ Conroy

Novel TKI Exhibits Durable Responses in HER2-Mutated NSCLC

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

Ariana Pelosci